Navigation Links
Alba Therapeutics Corporation Announces the Next Clinical Trial of Its Lead Compound, Larazotide Acetate and Promotions
Date:3/17/2009

BALTIMORE, March 17 /PRNewswire/ -- Alba Therapeutics Corporation announced today it will initiate further clinical studies for patients diagnosed with celiac disease with their lead compound, larazotide acetate. "Our most recent Phase IIb study, the largest trial with an investigational medication conducted in patients with celiac disease, was a randomized, double-blind, placebo controlled, dose ranging, multicenter study to determine the safety, tolerance and efficacy of larazotide acetate in 184 adults with controlled celiac disease during a gluten challenge. The data are promising and will be publicly presented at upcoming scientific meetings this spring," said Bruce Peacock, CEO of Alba Therapeutics. "Recently, Alba restructured to concentrate its efforts on advancing the clinical program for larazotide acetate, and we are now moving forward with initiating our next clinical trial in patients with celiac disease."

Additionally, Alba announced that Francisco Leon, MD, PhD has been promoted to Vice President and Chief Medical Officer. "I am very pleased to have Dr. Leon assume the responsibilities of CMO. His passion for developing a treatment for celiac disease is an inspiration to all Alba employees." Alba also announced that Dr. Linda Arterburn has been promoted to Vice President of Development. "Our team consists of a fine, talented group of people who are dedicated to help us meet the unmet medical needs of patients with celiac disease and other autoimmune and inflammatory diseases," said Bruce Peacock.

Francisco Leon, MD, PhD, formerly Vice President, Clinical Operations and Medical Affairs, has been promoted to Vice President and Chief Medical Officer. Dr. Leon is an immunologist with broad training in basic and clinical Immunology and a vocation for clinical development in the field of Mucosal Immunology. Prior to joining Alba in September 2007, Dr. Leon was a Director of Clinical Development, Inf
'/>"/>

SOURCE Alba Therapeutics Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. InteKrin Therapeutics Announces Enrollment Completion of 360 Patient, 24 week Phase 2b Study
2. Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer
3. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
4. ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimers Disease
5. BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine
6. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
7. Cerenis Therapeutics In-Licenses Intellectual Property for New Treatment of Aortic Valve Stenosis
8. PTC Therapeutics Completes Enrollment of Pivotal Trial in Muscular Dystrophy
9. DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round
10. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
11. Duska Therapeutics Completes Corporate Name Change to Cordex Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... FORT WORTH, Texas , Jan. 15, 2014  Humberto ... in Dermatology Achievement Award" from the Journal of ... Dermatology Aesthetic & Clinical Conference (ODAC). The event is January ... Florida . The ...
(Date:1/15/2014)... 2014  Manufacturers, suppliers and distributors of innovative medical-related ... their most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the ... the most litigious industry sectors of cases involving ...
(Date:1/15/2014)... Tegra Medical is very pleased to announce the appointment ... Chief Executive Officer.  Mark was promoted from his current role ... company,s four facilities in Massachusetts , ... Tegra Medical in 2012 with 20+ years of broad-based operations, ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... 15, 2011 Vantage Health (OTC:BB – ticker symbol ... tender submissions (the "tender", "tenders") have been accepted by ... Dar es Salaam. The tenders will not be adjudicated, ... any award in this respect, until December 02, 2011. ...
... VIEW, Calif., Sept. 15, 2011 VIVUS, Inc. (NASDAQ: ... it has reached agreement with officials of the Endocrine and ... plan that allows for an early resubmission of the QNEXA ... plan allows VIVUS to seek approval for an initial indication ...
Cached Medicine Technology:Vantage Health Submits Tender Documents for Tanzania Medical Stores Department and University of Dar es Salaam Procurement Tenders 2Vantage Health Submits Tender Documents for Tanzania Medical Stores Department and University of Dar es Salaam Procurement Tenders 3VIVUS Provides Regulatory Update on QNEXA 2VIVUS Provides Regulatory Update on QNEXA 3VIVUS Provides Regulatory Update on QNEXA 4
(Date:7/9/2014)... , , , , , ... , , , , ... the weapon was an SA80 assault rifle and the microphone is 50m downrange from the firer and approximately 30cm from the bullet... , ... , , , , ... , , , , , ...
(Date:7/9/2014)... allergic diseases has risen dramatically in Western societies. One ... to microorganisms and have fewer infections than previous generations, ... study by researchers at Sahlgrenska Academy, University of Gothenburg, ... maturation of the immune system in relation to allergic ... of the Vstra Gtaland Region, half of them on ...
(Date:7/8/2014)... longevity and cardiovascular health as other healthy mature individuals, ... American Journal of Transplantation . The findings may provide ... transplant professionals caring for them. , Over the past ... years and older has become more common. Given the ... the removal of a kidney could make older donors ...
(Date:7/8/2014)... The Department of Defense,s Defense Advanced Research Projects ... up to $2.5 million to develop an implantable ... stimulate neurons within the brain to help restore ... research builds on the understanding that memory is ... of the brain encode information, store it and ...
(Date:7/8/2014)... were found to be three times higher when auditors ... no auditors present, according to a study in a ... titled, "Quantification of the Hawthorne effect in hand hygiene ... cohort study," published today on-line in the BMJ ... Jocelyn Srigley, who did the study as part of ...
Breaking Medicine News(10 mins):Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7Health News:Study finds kidney donation safe for healthy older adults 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 3Health News:Health-care worker hand hygiene rates increase three-fold when auditors visible 2Health News:Health-care worker hand hygiene rates increase three-fold when auditors visible 3
... , Dec. 24th Vote Looming, AARP Calls on Senators to ... of Idaho,s Health Care Woes , BOISE, Idaho, Dec. 23 ... families this holiday season, rising health care costs are an issue ... woes grow increasingly worse, AARP is calling on Senators Mike Crapo ...
... in study lost bone mass within two years , WEDNESDAY, ... who received the "birth control shot" -- also known as ... percent of their bone mineral density in the hip and ... who had never given birth and who didn,t consume much ...
... rolls around and you,re deciding whether to have another glass ... of the future. A pair of Kansas State University ... long term are more likely to make positive decisions about ... eat, or their decision to wear sunscreen. "If you ...
... , , LOUISVILLE, Ky., Dec. 23 ... companies today called on Congress to drop language that would ... food and beverage products prior to the point of sale, ... The requirement is included in both the House and ...
... , , , NEW YORK, Dec. ... by the Center for Disease Control and Prevention (CDC) and ... that approximately 673,000 children aged 3-21 have been diagnosed with ... that children with autism need increased access to evidence-based interventions, ...
... mushroom commonly used in Chinese medicine, could be made more ... works. The research is funded by the Biotechnology and Biological ... of Nottingham. In research to be published in the ... of The University of Nottingham and her team have investigated ...
Cached Medicine News:Health News:AARP Urges Idaho Senators Not to be the Grinches That Stole Health Care Reform 2Health News:Contraceptive Depo-Provera May Weaken Bones 2Health News:K-State psychologists show that future-minded people make better decisions for their health 2Health News:K-State psychologists show that future-minded people make better decisions for their health 3Health News:Vend Marketing Institute Calls on Congress to Modify Calorie Disclosure Requirement: Supports Existing Disclosure Which Is More Complete and Effective 2Health News:Vend Marketing Institute Calls on Congress to Modify Calorie Disclosure Requirement: Supports Existing Disclosure Which Is More Complete and Effective 3Health News:Autism Treatment Crisis: Insufficient Number of Providers to Meet Alarming Increase in Need 2Health News:Autism Treatment Crisis: Insufficient Number of Providers to Meet Alarming Increase in Need 3Health News:New insights into mushroom-derived drug promising for cancer treatment 2
... In addition to three conventional measurement modes ... also incorporates a new axial length measuring ... by calculating sonic velocity for conversion at ... length by calculating each tissues sonic velocity ...
... with graphic display and IOL power ... combination units include firmware module with ... II formulas. Audible tones increase in ... visual axis. Constant tone when alignment ...
... Artemis is the world's first very high ... 3D Arc-scanning technology, Artemis provides microscopic resolution ... cornea and anterior segments of the human ... (VHF) ultrasound eye scanner. In use, the ...
... The ISYSTEM-ABD ("I-cubed") is an exceptionally ... an analog oscilloscope (static deflection) display. ... resolution than low cost video monitors. ... syneresis, inflammatory cells, as well as ...
Medicine Products: